Efficacy of Tegoprazan in Patients With Functional Dyspepsia: A Prospective, Multicenter, Single-arm Study
Journal of Neurogastroenterology and Motility · 30.07.2024 · 30 (3) · 313-321
DOI: 10.5056/jnm23150 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurogastroenterology and Motility, online erschienen am 04.05.2024. Verfasst von Cheal Wung Huh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HK inno.N Corp..
Abstract (Originalsprache)
Background/Aims: Acid-suppressive drugs, such as proton pump inhibitors (PPIs), are treatment options for functional dyspepsia (FD). However, the efficacy of potassium-competitive acid blockers (P-CABs) in treating FD has not yet been established. This prospective multicenter clinical trial-based study aimed to assess the efficacy and safety of tegoprazan as a P-CAB treatment in patients with FD.
Methods
FD was diagnosed using the Rome IV criteria. All patients received tegoprazan 50 mg once daily for 8 weeks. Dyspeptic symptoms were assessed using a dyspepsia symptom questionnaire (5-point Likert scale, Nepean Dyspepsia Index-Korean [NDI-K], and gastroesophageal reflux disease-health-related quality of life [GERD-HRQL]). The main outcome was satisfactory symptom relief rates at 8 weeks.
Results
In this study, from the initial screening of 209 patients, 173 were included in the per-protocol set analysis. Satisfactory symptom relief rates at 8 and 4 weeks were 86.7% and 74.6%, respectively. In addition, the NDI-K and GERD-HRQL scores significantly improved at 8 and 4 weeks compared with the baseline scores. The efficacy of tegoprazan was not influenced by the FD subtype or Helicobacter pylori status. In patients with overlapping FD and GERD, there was a greater improvement in the NDI-K and GERD-HRQL scores than in patients with FD symptoms only. No serious drug-related adverse events occurred during this study.
Conclusion
Tegoprazan (50 mg) administered once daily provided satisfactory symptom relief for FD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Jinju, Gyeongsangnam-do, Korea.
- Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.
ORCID-Profile: Cheal Wung Huh, Young Hoon Youn
Förderung
- HK inno.N Corp.
Zitieren
APA
Huh, C. W., Youn, Y. H., Jung, D. H., Cha, R. R., Kim, Y. J., Jung, K., Song, K. H., Bang, K. B., Tae, C. H., Choi, S. I., Shin, C. M., & Functional Dyspepsia Research Group Under the Korean Society of Neurogastroenterology and Motility (2024). Efficacy of Tegoprazan in Patients With Functional Dyspepsia: A Prospective, Multicenter, Single-arm Study. Journal of Neurogastroenterology and Motility, 30(3), 313-321. https://doi.org/10.5056/jnm23150
Vancouver
Huh CW, Youn YH, Jung DH, Cha RR, Kim YJ, Jung K, et al. Efficacy of Tegoprazan in Patients With Functional Dyspepsia: A Prospective, Multicenter, Single-arm Study. Journal of Neurogastroenterology and Motility. 2024;30(3):313-321. doi:10.5056/jnm23150
BibTeX
@article{Huh2024,
author = {Huh, Cheal Wung and Youn, Young Hoon and Jung, Da Hyun and Cha, Ra Ri and Kim, Yeon Ji and Jung, Kyoungwon and Song, Kyung Ho and Bang, Ki Bae and Tae, Chung Hyun and Choi, Soo In and Shin, Cheol Min and Functional Dyspepsia Research Group Under the Korean Society of Neurogastroenterology and Motility, Functional Dyspepsia Research Group Under the Korean Society of Neurogastroenterology and Motility},
title = {Efficacy of Tegoprazan in Patients With Functional Dyspepsia: A Prospective, Multicenter, Single-arm Study},
journal = {Journal of Neurogastroenterology and Motility},
year = {2024},
volume = {30},
number = {3},
pages = {313--321},
doi = {10.5056/jnm23150}
}
EUVIMED